Austrian Start-up Ugichem Tackles RNA Delivery Issue
By Nuala Moran
Staff Writer
Staff Writer
LONDON – In the past year the lure of gene silencing as a route to address disease has prompted a revival in the field. But it remains the case that the difficulties of delivering RNA-based drugs continue to slow the pace of development and limit their use to the liver or tumor tissues, or to tissues where local administration is possible.
